Evidence for octreotide subcutaneously in the treatment of acromegaly.
作者信息
Liuzzi A, Oppizzi G
机构信息
Division of Endocrinology, Italian Auxological Centre, IRCCS St Giuseppe Hospital, Piancavallo, Italy.
出版信息
J Endocrinol. 1997 Oct;155 Suppl 1:S61-5.
PMID:9389999
Abstract
摘要
相似文献
1
Evidence for octreotide subcutaneously in the treatment of acromegaly.
J Endocrinol. 1997 Oct;155 Suppl 1:S61-5.
2
Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
Clin Pharmacol Ther. 2005 Jul;78(1):69-80. doi: 10.1016/j.clpt.2005.04.003.
3
[Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
Orv Hetil. 2002 May 12;143(19 Suppl):1062-6.
4
[Treatment of therapy-resistant acromegaly using Sandostatin].
Z Gastroenterol. 1990 Sep;28 Suppl 2:29-31.
5
All aboard for octreotide.
Lancet. 1990 Oct 13;336(8720):909-11.
6
Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
Clin Endocrinol (Oxf). 2004 Aug;61(2):224-31. doi: 10.1111/j.1365-2265.2004.02084.x.
7
[Experience in treating acromegalic patients with long-acting octreotide].
Orv Hetil. 2002 May 12;143(19 Suppl):1066-70.
8
Lipoatrophy induced by subcutaneous administration of octreotide in the treatment of acromegaly.
Exp Clin Endocrinol Diabetes. 2005 Jun;113(6):340-3. doi: 10.1055/s-2005-837664.
9
Population pharmacodynamic analysis of octreotide in acromegalic patients.
Clin Pharmacol Ther. 2003 Jan;73(1):95-106. doi: 10.1067/mcp.2003.6.
10
Pegvisomant: new preparation. A last resort in acromegaly.
Prescrire Int. 2005 Feb;14(75):10-3.
引用本文的文献
1
Gender-related differences in growth hormone-releasing pituitary adenomas. A clinicopathological study.
Pituitary. 2002;5(4):247-53. doi: 10.1023/a:1025329900839.
2
Reevaluation of conventional pituitary irradiation in the therapy of acromegaly.
Pituitary. 1999 Jun;2(1):55-62. doi: 10.1023/a:1009969921497.
Zotero 插件